LAPATINIB

Indications

It is tryrosine kinase inhibitor used to treat breast cancer with HER2/neu+ receptors.

Dosage

1250mg to 1500mg per day depending on the combination of drug used.

Contra-Indications

Known hypersensitivity to Lapatinib.

Special Precautions

Decreased left ventricular ejection fraction (LVEF) hepatotoxicity. Monitor pulmonary symptoms indicative of interstitial lung disease. Concomitant use with CYP3A4 inducers or inhibitors. Pregnancy & Lactation. Children. Elderly.

Side Effects

More seen with combination of other drugs. Decreased LVEF, fatigue; headache, Palmar-plantar erythrodysesthesia; diarrhea; nausea; vomiting; stomatitis. Abnormal hemoglobin, AST, ALT, total bilirubin, Neutrophils, Platelets. Dyspnea, Mucosal inflammation.

Drug Interactions

CYP3A4 inducers (eg rifampin, carbamazepine or phenytoin) & CYP2C8 inhibitors (eg ketoconazole, itraconazole or grapefruit juice); esomeprazole; midazolam; paclitaxel IV; irinotecan; topotecan; digoxin; rosuvastatin.